drugset
drugset / Trial / NCT06374290

Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia

NCT06374290 ↗

Phase 1 Terminated 2 enrolled The University of Texas Health Science Center, Houston
NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to assess the feasibility and safety of injectable naltrexone (NTX;380 mg) in conjunction with oral bupropion (BUP; 450 mg daily)NTX-BUP administration among individuals with schizophrenia spectrum disorders that smoke cigarettes and to evaluate change on smoking-related measures and symptoms of schizophrenia.

Timeline

Start
2024-07-16
Primary completion
2024-12-04
Completion
2024-12-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 450 mg Oral
Subject Naltrexone Small molecule 380 mg Intramuscular

Indications

No indication recorded.